Opioid model

Dynorphin may also influence nociception at the spinal level. The levels of prodynorphin mRNA and immunoreactive dynorphin increase in the chronic inflammatory arthritic model (158). Dynorphin also inhibits morphine or P-endorphin-induced analgesia in naive animals and enhances analgesia in tolerant animals, indicating that this peptide may have a regulatory role in opioid analgesia (159). This effect does not appear to be mediated by a classical opioid receptor, since des-tyrosine dynorphin, which does not bind to opioid receptors, also antagonizes morphine analgesia (160). 

Ligand recognition in the opioid receptors by modeling methods and design of opioids 98YZ1. 

They act as analgesics by inhibiting release of nociceptive neurotransmitters from primary afferent terminals as well as by depressing post-synaptic potentials on second order neurons. Opioid receptors are also present on some nociceptors and their expression and peripheral transport is increased upon peripheral inflammation. Peripheral opioid analgesia has been established in animal models. Although clinical studies have yielded mixed results so far, this field holds great promise. Despite side effects, such as euphoria, dysphoria, sedation, respiratory depression and obstipation and tolerance and dependence phenomena which arise upon... 

Benzodiazepines and similar agents occupy a position of intermediate abuse potential, compared with most other sedative-hypnotics (Griffiths and Weerts 1997). Animal models of abuse habihty indicate that the reinforcing effects of benzodiazepines are less pronounced than are those of the barbiturates, opioids, and stimulants. Differences in abuse potential within the class have not been consistently demonstrated however, most chnicians agree that benzodiazepines with a rapid onset and short duration of action pose the greatest risk in susceptible individuals. 

In this chapter, we review the interactions at the level of protein function, between opioid receptors and chemokine receptors, using both in vitro and in vivo model systems. As a part of this discussion, we also describe our current understanding of the biochemical pathway(s) that are involved in the heterologous desensitization process between these groups of receptors. 

Preliminary data indicate that in the reserpinised rat or MPTP marmoset, the enkephalin agonist (SNC80) reduces PD-like symptoms without causing increased activity, i.e. no trend to dyskinesias. Enadoline, a dynorphin-like kappa opioid agonist also has similar effects in the same models. Whether it would be similar in humans remains to be seen. 

Maneuf, YP, Mitchell, IJ, Crossman, AR, Woodruff, GN and Brotchis, JM (1995) Functional implications of Kappa opioid receptor mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models. Brain Res. 683 102-108. 

P.P. Mager, The Masca model of pharmacochemistry II. Rational empiricisms in the multivariate analysis of opioids. In Drug Design, (E.J. Ariens, Ed.), Vol. X. Academic Press, New York, 1980, pp. 343-401. 

Molecular modelling of opioid receptor-ligand complexes, 40 (2002) 107 Molecularly imprinted polymers,... 

Wilkes BC, Schiller, PW. Comparative analysis of various proposed models of the receptor-bound conformation of TIP(P)-related opioid antagonists. Biopolymers (Peptide Sci) 1995 37 391-400. 

Paterlini G, Portoghese P, Ferguson D. Molecular simulation of dynorphin A-(1—10) binding to extracellular loop 2 of the kappa opioid receptor. A model for receptor activation. J Med Chem 1997 40 3254-3262. 

Filizola, M. and Weinstein, H. (2002) Structural models for dimerization of G protein coupled receptors the opioid receptor homodimers. Biopolymers (Peptide Sci.) 66, 317-325. 

---